

Attention Deficit Hyperactivity Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/A26441DAB7E1EN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: A26441DAB7E1EN

Abstracts

The 7 major attention deficit hyperactivity disorder markets reached a value of US\$ 9.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 13.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.23% during 2024-2034.

The attention deficit hyperactivity disorder market has been comprehensively analyzed in IMARC's new report titled "Attention Deficit Hyperactivity Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Attention deficit hyperactivity disorder (ADHD) refers to a neurodevelopmental condition that can affect people of all ages. The indications of the ailment can be grouped into two main categories: inattention and hyperactivity/impulsivity. Inattention symptoms may include difficulty with organization and time management, forgetfulness, distractibility, problems with sustained attention and task completion, etc. Hyperactivity/impulsivity symptoms are fidgeting, restlessness, difficulty sitting still, impulsivity, interrupting or speaking out of turn, etc. Individuals with ADHD may also struggle with social skills, emotion regulation, and academic or occupational performance. Diagnosing the ailment typically involves a comprehensive evaluation by a qualified healthcare professional. The assessment includes a detailed medical history, including information about developmental milestones, family history, and past as well as present symptoms. Medical professionals also use rating scales or checklists to help identify signs and evaluate their severity. In some cases, they may perform additional testing, such as neurological or psychological testing, to rule out other conditions that resemble ADHD indications.

The growing cases of developmental variations in some regions of the brain that are involved in attention and impulse control, such as the prefrontal cortex, basal ganglia,

cerebellum, etc., are primarily driving the attention deficit hyperactivity disorder market. Furthermore, the widespread adoption of various stimulant medications, including Ritalin and Adderall, which work by increasing the levels of dopamine and norepinephrine in the brain to improve attention as well as reduce hyperactivity and impulsivity, is creating a positive outlook for the market. Apart from this, the escalating utilization of neurofeedback for helping individuals with ADHD regulate their brain activity and improve symptoms associated with the ailment is acting as another significant growth-inducing factor. Additionally, the rising demand for cognitive-behavioral therapy (CBT) that focuses on changing thought patterns and behaviors in individuals who struggle with negative self-talk, anxiety, and depression is also augmenting the market growth. Moreover, the emerging popularity of non-stimulant medications on account of their several associated benefits, including lower risk of abuse or dependence, fewer side effects, and better effectiveness in treating both ADHD symptoms as well as co-occurring conditions, is expected to drive the attention deficit hyperactivity disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the attention deficit hyperactivity disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for attention deficit hyperactivity disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the attention deficit hyperactivity disorder market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the attention deficit hyperactivity disorder market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the attention deficit hyperactivity disorder market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current attention deficit hyperactivity disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the attention deficit hyperactivity disorder market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the attention deficit hyperactivity disorder market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the attention deficit hyperactivity disorder market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of attention deficit hyperactivity disorder across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of attention deficit hyperactivity disorder by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of attention deficit hyperactivity disorder by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with attention deficit hyperactivity disorder across the seven major markets?

What is the size of the attention deficit hyperactivity disorder patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of attention deficit hyperactivity disorder?

What will be the growth rate of patients across the seven major markets?

Attention Deficit Hyperactivity Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for attention deficit hyperactivity disorder drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the attention deficit hyperactivity disorder market?

What are the key regulatory events related to the attention deficit hyperactivity disorder market?

What is the structure of clinical trial landscape by status related to the attention deficit hyperactivity disorder market?

What is the structure of clinical trial landscape by phase related to the attention deficit hyperactivity disorder market?

What is the structure of clinical trial landscape by route of administration related to the attention deficit hyperactivity disorder market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Source
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ATTENTION DEFICIT HYPERACTIVITY DISORDER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 ATTENTION DEFICIT HYPERACTIVITY DISORDER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 ATTENTION DEFICIT HYPERACTIVITY DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 ATTENTION DEFICIT HYPERACTIVITY DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 ATTENTION DEFICIT HYPERACTIVITY DISORDER - UNMET NEEDS

10 ATTENTION DEFICIT HYPERACTIVITY DISORDER - KEY ENDPOINTS OF TREATMENT

11 ATTENTION DEFICIT HYPERACTIVITY DISORDER - MARKETED PRODUCTS

- 11.1 List of Attention Deficit Hyperactivity Disorder Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Azstarys (Serdexmethylphenidate/dexmethylphenidate) - Zevra Therapeutics
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Focalin (Dexmethylphenidate) - Celgene/Novartis
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Vyvanse (Lisdexamfetamine) - Shionogi/Takeda
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Quillivant XR (Methylphenidate extended-release oral suspension) - Tris Pharma
 - 11.1.4.1 Drug Overview
 - 11.1.4.1 Mechanism of Action
 - 11.1.4.2 Regulatory Status
 - 11.1.4.3 Clinical Trial Results
 - 11.1.4.4 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 ATTENTION DEFICIT HYPERACTIVITY DISORDER - PIPELINE DRUGS

12.1 List of Attention Deficit Hyperactivity Disorder Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Centanafadine - Otsuka Pharmaceutical
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
- 12.1.2 PDC1421 - BioLite, Inc.
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status

12.1.3 CTX 1301 - Cingulate Therapeutics

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 Mazindol - NLS Pharmaceuticals Ltd

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

12.1.5 CX717 - RespireRx

12.1.5.1 Drug Overview

12.1.5.2 Mechanism of Action

12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. ATTENTION DEFICIT HYPERACTIVITY DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ATTENTION DEFICIT HYPERACTIVITY DISORDER – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 ATTENTION DEFICIT HYPERACTIVITY DISORDER - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Attention Deficit Hyperactivity Disorder - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

- 15.2.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Attention Deficit Hyperactivity Disorder - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Attention Deficit Hyperactivity Disorder - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Attention Deficit Hyperactivity Disorder - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Attention Deficit Hyperactivity Disorder - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Attention Deficit Hyperactivity Disorder - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)

- 15.7.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Attention Deficit Hyperactivity Disorder - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Attention Deficit Hyperactivity Disorder - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Attention Deficit Hyperactivity Disorder - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Attention Deficit Hyperactivity Disorder - Access and Reimbursement Overview

16 ATTENTION DEFICIT HYPERACTIVITY DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Attention Deficit Hyperactivity Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A26441DAB7E1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A26441DAB7E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

